These findings highlight the importance of considering SLEDAI, Hb, CRP, ESR, and age as crucial factors in the clinical management of SLE patients and the need for further investigation into their potential therapeutic implications. This evidence concerns the gene GSTM1 and systemic lupus erythematosus.